 | | Vol. 11.47 – 1 December, 2020 |
| |
|
|
| Scientists used single-cell and bulk assay for transposase-accessible chromatin sequencing on human HSCs and hematopoietic stem and progenitor cell subsets to uncover chromatin accessibility signatures, one including long-term (LT)-HSCs and another excluding LT-HSCs.
[Cell Stem Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers performed a longitudinal multi-omics study using a two-centre cohort of 14 patients. They analyzed the bulk transcriptome, bulk DNA methylome, and single-cell transcriptome of peripheral blood samples harvested from up to five time points.
[Immunity] |
|
|
|
| Scientists functionally investigated primary mouse lymphomas that formed in recipient mice of Eµ-myc transgenic HSCs stably transduced with naturally occurring NF-kB mutants.
[Blood] |
|
|
|
| Investigators showed that a knock-in reporter mouse for the stem cell gene Musashi 2 allowed identification of leukemia stem cells in aggressive myeloid malignancies, and provided a strategy for defining their core dependencies.
[Nature Communications] |
|
|
|
| Scientists evaluated the consequences of retinoid-inducible nuclear factor (RINF) silencing on cytokineinduced erythroid differentiation of human primary CD34+ progenitors.
[Haematologica] |
|
|
|
| To predict side effects of therapeutic MCL-1 inhibition on the human hematopoietic system, the authors used RNAi and the small molecule inhibitor S63845 on cord blood-derived CD34+ cells.
[Haematologica] |
|
|
|
| Researchers analyzed clonal hematopoiesis (CH) in blood samples from a pair of twin astronauts over four years in bulk and fractionated cell populations using a targeted CH panel, linked-read whole-genome sequencing, and deep RNA sequencing.
[Cell Reports] |
|
|
|
| To derive definitive hematopoietic stem/precursor cells from human embryonic stem cells, scientists differentiated mesodermally specified embryoid bodies on gelatin-coated plates in serum/feeder-free conditions.
[Stem Cell Research & Therapy] |
|
|
|
| Investigators resolved human hematopoietic populations at the earliest hematopoiesis stage by single-cell RNA-seq. They characterized the distinct molecular profiling between early primitive and definitive hematopoiesis in both human embryonic stem cell differentiation and early embryonic development.
[Cell Discovery] |
|
|
|
| The quantity and erythroid differentiation of hematopoietic stem and progenitor cells (HSPCs) were affected by myeloma cell infiltration in the bone marrow. The master regulators of erythropoiesis, GATA1 and KLF1, were obviously downregulated in myeloma HSPCs.
[Scientific Reports] |
|
|
|
| Scientists report that SON, a chromosome 21-encoded DNA- and RNA-binding protein, inhibits megakaryocytic differentiation by suppressing RUNX1 and the megakaryocytic gene expression program.
[Cancer Gene Therapy] |
|
|
|
| Researchers investigated the mobilization efficacy of repeated AMD3100 dosages in the non-human primate and humanized mouse models. In non-human primates they demonstrated effective mobilization after the first AMD3100 administration but significantly poorer response in CD34+ and HSC-enriched CD90+ cells with subsequent doses of the drug.
[Experimental Hematology] |
| |
|
|
| In this retrospective study, scientists described transplant characteristics of pediatric patients who underwent HSC transplantation in Switzerland and how these characteristics changed over time, compared self-reported pulmonary outcomes between transplanted and non-transplanted survivors, and investigated risk factors for the reported pulmonary outcomes.
[Bone Marrow Transplantation] |
|
|
|
|
| The authors summarize the pathophysiology of emergency myelopoiesis and the role of myeloid-derived suppressor cells, impaired erythropoiesis, as well as the mobilization of hematopoietic stem/progenitor cells from the bone marrow.
[Shock] |
|
|
|
|
| Antengene Corporation Limited announced that the National Medical Products Administration has approved the clinical trial of ATG-016 in patients with intermediate and higher risk myelodysplastic syndrome according to the Revised International Prognostic Scoring System after the failure of hypomethylating agents based therapy. The trial is a Phase I/II, single-arm, open-label clinical study, aiming to evaluate the pharmacokinetics, safety and efficacy of ATG-016 monotherapy.
[Antengene Corporation Limited] |
|
|
|
| Celularity, Inc. announced that the first patient was dosed in its Phase I clinical study of human placental hematopoietic stem cell-derived natural killer cells (CYNK-001) in adults with recurrent glioblastoma multiforme.
[Celularity, Inc. (PR Newswire Association LLC.)] |
|
|
|
|
| October 27 – October 29, 2021
Tokyo, Japan |
|
|
|
|
|
| | Rubius Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | New York Blood Center – New York, New York, United States |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
